Clinical outcomes of bacillus Calmette-Guérin instillation therapy for carcinoma in situ of urinary bladder

International Journal of Urology

Volumn 15, Issue 4, 2008, Pages 309-313

  Takenaka, Atsushi ^a   Yamada, Yuji ^b   Miyake, Hideaki ^a   Hara, Isao ^c   Fujisawa, Masato ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HYOGO PREFECTURAL AMAGASAKI GENERAL MEDICAL CENTER   (Japan)

^c WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Bacillus Calmette Guerin; Bladder carcinoma in situ; Instillation therapy

Indexed keywords

BCG VACCINE;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOMA IN SITU; CLINICAL TRIAL; CYSTECTOMY; DRUG INSTILLATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BIOPSY; UNSPECIFIED SIDE EFFECT; URINARY TRACT;

ADULT; AGED; AGED, 80 AND OVER; BCG VACCINE; CARCINOMA IN SITU; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 41749125908     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2008.02012.x     Document Type: Article

References (21)

1. Lamm DL. Carcinoma in situ. Urol. Clin. North Am. 1992 19:499 508.
2. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J. Urol. 1976 116:180 3.
3. Lamm DL, Blumenstein BA, Crawford ED et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl. J. Med. 1991 325:1205 9.
4. Smith JA Jr, Labasky RF, Cockett AT, Fracchia JA, Montie JE, Rowland RG. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J. Urol. 1999 162:1697 701.
5. Akaza H, Hinotsu S, Aso Y, Kakizoe T, Koiso K. Bacillus Calmette-Guerin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. The Bladder Cancer BCG Study Group. Cancer 1995 75:552 9.
6. Akaza H, Koiso K, Ozono S et al. A clinical study of PMCJ-9 (Bacillus Calmette-Guerin Connaught strain) treatment of superficial bladder cancer and carcinoma in situ of the bladder. Jpn J. Clin. Oncol. 2003 33:382 90.
7. Hinotsu S, Akaza H, Isaka S et al. Sustained prophylactic effect of intravesical bacille Calmette-Guerin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study. Urology 2006 67:545 9.
8. Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J. Urol. 1997 158:62 7.
9. Jakse G, Hall R, Bono A et al. Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861. Eur. Urol. 2001 40:144 50.
10. Talic RF, Hargreave TB, Bishop MC, Kirk D, Prescott S. Intravesical Evans bacille Calmette-Guerin for carcinoma in situ of the urinary bladder. Scottish Urological Oncology Group. Br. J. Urol. 1994 73:645 8.
11. Lamm DL. Preventing progression and improving survival with BCG maintenance. Eur. Urol. 2000 37 (Suppl 1 9 15.
12. Takashi M, Katsuno S, Yuba H, Ohshima S, Wakai K, Ohno Y. Possible factors affecting response to intravesical bacillus Calmette-Guerin (Tokyo 172 strain) therapy for carcinoma in situ of the bladder: a multivariate analysis. Int. Urol. Nephrol. 1998 30:713 22.
13. Andius P, Damm O, Holmang S. Prognostic factors in patients with carcinoma in situ treated with intravesical bacille Calmette-Guerin. Scand. J. Urol. Nephrol. 2004 38:285 90.
14. Griffiths TR, Charlton M, Neal DE, Powell PH. Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance. J. Urol. 2002 167:2408 12.
15. Ovesen H, Horn T, Steven K. Long-term efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ: relationship of progression to histological response and p53 nuclear accumulation. J. Urol. 1997 157:1655 9.
16. van Gils-Gielen RJ, Witjes WP, Caris CT, Debruyne FM, Witjes JA, Oosterhof GO. Risk factors in carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group. Urology 1995 45:581 6.
17. Orsola A, Palou J, Xavier B, Algaba F, Salvador J, Vicente J. Primary bladder carcinoma in situ: assessment of early BCG response as a prognostic factor. Eur. Urol. 1998 33:457 63.
18. Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J. Urol. 2005 174:86 91 discussion -2.
19. Lamm DL, Blumenstein BA, Crissman JD et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J. Urol. 2000 163:1124 9.
20. Palou J, Laguna P, Millan-Rodriguez F, Hall RR, Salvador-Bayarri J, Vicente-Rodriguez J. Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors. J. Urol. 2001 165:1488 91.
21. Sylvester RJMA, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J. Urol. 2002 168:1964 70.